Wildtype for KRAS and a strong EGFR expression were detected in >90% of the tumor cells, thus addition of the EGFR monoclonal antibody cetuximab or panitumumab to a platinum-based chemotherapy was recommended. Here, KRAS is linked to neoplasm.